銀輪股份(002126.SZ)擬與聖達生物等共同投資銀康生物
格隆匯1月3日丨銀輪股份(002126.SZ)公佈,公司於2020年1月2日召開的第七屆董事會第十九次會議審議通過了《關於對外投資暨關聯交易的議案》。公司擬與浙江聖達生物藥業股份有限公司(“聖達生物”)、姑蘇(廣州)投資合夥企業(有限合夥)(“姑蘇投資”)共同投資天台銀康生物醫藥有限公司(“銀康生物”或“標的公司”),其中公司擬以現金人民幣3060萬元向銀康生物進行投資,其中認繳銀康生物新增註冊資本1500萬元,其餘1560萬元計入銀康生物資本公積。增資完成後,持有銀康生物20.2634%的股權,資金來源為公司自有資金。
因公司董事長徐小敏持有銀康生物18.36%股權(此次增資前),是銀康生物的法定代表人、執行董事,公司副董事長陳不非擔任聖達生物董事,此次交易構成關聯交易。
近年來隨着經濟的發展,生活水平的提高,人們對健康的重視程度也越來越高,尤其隨着人口老齡化的加劇,帶動了中國醫藥行業的飛速發展,同時也帶來了巨大的投資機會。
銀康生物在研IBI304項目(重組人VEGF受體-FC融合蛋白)有廣闊的市場前景。聖達生物有良好的生物製藥行業基礎,姑蘇投資為專注於生物醫藥行業的投資機構。此次投資有利於深化各參與方的合作及優勢資源共享,為公司及股東創造合理的投資回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.